| Reference | 1:Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. Sano T, Utsumi D, Amagase K, Matsumoto K, Tominaga M, Higuchi K, Takeuchi T, Kato S.J Physiol Pharmacol. 2017 Feb;68(1):79-90. PMID: 28456772 Free Article<br />
2:Studies of DNA-binding properties of lafutidine as adjuvant anticancer agent to calf thymus DNA using multi-spectroscopic approaches, NMR relaxation data, molecular docking and dynamical simulation. Yang H, Tang P, Tang B, Huang Y, He J, Li S, Li H.Int J Biol Macromol. 2017 Jun;99:79-87. doi: 10.1016/j.ijbiomac.2017.02.062. Epub 2017 Feb 22. PMID: 28235605 <br />
3:Interaction of lafutidine in binding to human serum albumin in gastric ulcer therapy: STD-NMR, WaterLOGSY-NMR, NMR relaxation times, Tr-NOESY, molecule docking, and spectroscopic studies. Yang H, Huang Y, He J, Li S, Tang B, Li H.Arch Biochem Biophys. 2016 Sep 15;606:81-9. doi: 10.1016/j.abb.2016.07.016. Epub 2016 Jul 22. PMID: 27457418 <br />
4:Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects. Li S, Xu M, Li H, Du J, Li W.Adv Ther. 2016 Oct;33(10):1704-1714. Epub 2016 Jul 21. PMID: 27444313 <br />
5:Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. Takenaka R, Okada H, Kawano S, Komazawa Y, Yoshinaga F, Nagata S, Inoue M, Komatsu H, Onogawa S, Kushiyama Y, Mukai S, Todo H, Okanobu H, Manabe N, Tanaka S, Haruma K, Kinoshita Y.World J Gastroenterol. 2016 Jun 21;22(23):5430-5. doi: 10.3748/wjg.v22.i23.5430. PMID: 27340360 Free PMC Article<br />
6:Addition of lafutidine can improve disease activity and lead to better quality of life in refractory cholinergic urticaria unresponsive to histamine H1 antagonists. Hatakeyama M, Fukunaga A, Washio K, Ogura K, Yamada Y, Horikawa T, Nishigori C.J Dermatol Sci. 2016 May;82(2):137-9. doi: 10.1016/j.jdermsci.2016.02.001. Epub 2016 Feb 8. No abstract available. PMID: 26896422 <br />
7:Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Kim EH, Lee YC, Chang YW, Park JJ, Chun HJ, Jung HY, Kim HS, Jeong HY, Seol SY, Han SW, Choi MG, Park SH, Lee OJ, Jung JT, Lee DH, Jung HC, Lee ST, Kim JG, Youn SJ, Kim HY, Lee SW.Dig Dis Sci. 2015 Jun;60(6):1724-32. doi: 10.1007/s10620-014-3489-4. Epub 2014 Dec 23. PMID: 25532503 <br />
8:Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Namikawa T, Munekage E, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K.Anticancer Res. 2014 Dec;34(12):7297-301. PMID: 25503163 <br />
9:Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia. Maity S, Choudhury S, Hazra A, Das AK.Indian J Pharmacol. 2014 Sep-Oct;46(5):498-502. doi: 10.4103/0253-7613.140580. PMID: 25298578 Free PMC Article<br />
10:Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability. Patil S, Talele GS.Drug Deliv. 2015 May;22(3):312-9. doi: 10.3109/10717544.2013.877099. Epub 2014 Jan 29. PMID: 24471787
|
